In silico study of coumarins and quinolines derivatives as potent inhibitors of sars-cov-2 main protease
Author
dc.contributor.author
Yáñez, Osvaldo
Author
dc.contributor.author
Osorio, Manuel Isaías
Author
dc.contributor.author
Uriarte, Eugenio
Author
dc.contributor.author
Areche Medina, Carlos Alberto
Author
dc.contributor.author
Tiznado, William
Author
dc.contributor.author
Pérez Donoso, José M.
Author
dc.contributor.author
García Beltrán, Olimpo José
Author
dc.contributor.author
González Nilo, Fernando Danilo
Admission date
dc.date.accessioned
2022-01-10T21:09:25Z
Available date
dc.date.available
2022-01-10T21:09:25Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Frontiers in Chemistry, February 2021, Volume 8, Article 595097
es_ES
Identifier
dc.identifier.other
10.3389/fchem.2020.595097
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/183634
Abstract
dc.description.abstract
The pandemic that started in Wuhan (China) in 2019 has caused a large number of deaths,
and infected people around the world due to the absence of effective therapy against
coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation
requires the activity of the main viral protease (Mpro), so its inhibition stops the progress of
the disease. To evaluate possible inhibitors, a computational model of the SARS-CoV-2
enzyme Mpro was constructed in complex with 26 synthetic ligands derived from
coumarins and quinolines. Analysis of simulations of molecular dynamics and molecular
docking of the models show a high affinity for the enzyme (ΔEbinding between −5.1 and
7.1 kcal mol−1). The six compounds with the highest affinity show Kd between 6.26 × 10–6
and 17.2 × 10–6, with binding affinity between −20 and −25 kcal mol−1, with ligand efficiency
less than 0.3 associated with possible inhibitory candidates. In addition to the high
affinity of these compounds for SARS-CoV-2 Mpro, low toxicity is expected considering
the Lipinski, Veber and Pfizer rules. Therefore, this novel study provides candidate
inhibitors that would allow experimental studies which can lead to the development of
new treatments for SARS-CoV-2.
es_ES
Patrocinador
dc.description.sponsorship
Ministry of Education
Ministry of Industry, Commerce and Tourism
ICETEX, Programme Ecosistema Cientifico-Colombia Cientifica
Francisco Jose de Caldas Fund RC-FP44842-212-2018
ANID/PIA/ACT192144
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States